Volition announces two poster presentations at esmo's european lung cancer congress 2025

Studies demonstrate how volition's nu.q®h3k27me3 biomarker, when combined with ctdna, may improve the prognostic value for overall survival and could help inform treatment decisions in nsclc; and how volition's nu.q® h3.1, low-cost immunoassay may be utilized  for the early identification of subjects at high risk of cancer henderson, nev. , march 28, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announces two poster presentations at the european society for medical oncology (esmo)'s european lung cancer congress 2025 (elcc 2025).
VNRX Ratings Summary
VNRX Quant Ranking